Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|February 2, 2015
Gene Expression Profiling for Smoldering Myeloma Patients
Author(s)Gareth Morgan, MD, PhD
Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.
Advertisement
Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.
Clinical pearls:
- Smoldering myeloma doesn’t act as a single disease.
- Gene expression profiling, a clinical staging system based on four genes, is used as an approach to identify high-risk progression of this disease. It is also used as technique to determine which patients would progress in one year.
- Intervention studies or treatments can be used following gene expression profiling.
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5